Search the Community
Showing results for tags 'spotting'.
Found 3 results
Hello! I'm new to this website as far as officially being a member but ever since I was diagnosed with celiac disease two years ago, I have often run to this site for help! This leads me to my question at hand...does anyone else (women of course) have an issue with irregular spotting 'down there' after working out? I have been experiencing a lot of GI and reproductive problems lately so, after dealing with every doctor under the sun, I have been told that I'm fine. They don't know what's causing my lower back cramping and occasional spotting but everything else can be attributed to to my Celiac Disease. Does anyone else get these two symptoms? The lower back cramping often comes along with an upset stomach/D so I'm not too terribly concerned about it and I guess it's just normal...the irregular spotting has me worried, though. I'm not a huge fan of the obgyn I currently am able to go to so I'm not quite sure she really covered all her bases and she doesn't seem to understand how much celiac disease factors into my entire body, not just my stomach. Anyone else experience irregular spotting after working out? I'm just trying to figure out if this is in any way tied to my celiac disease or if I need to finally bite the bullet and go hunt down a better obgyn.
Jefferson Adams posted an article in Celiac Disease Diagnosis, Testing & TreatmentCeliac.com 09/25/2008 - Mucosal inflammation of the small intestine, coupled with damage to intestinal villi, is a classic indication of celiac disease. Recently, doctors have begun to embrace the idea that some patients with positive celiac blood tests may have mucosal lesions that are too small to appear on routine histopathological analysis. In the first study of its kind, a team of researchers based in Ireland set out to analyze enterocyte morphology and cytoskeletal structures using a high content analysis technology. The research team was made up of doctors Bashir M. Mohamed, Conleth Feighery, Yvonne Williams, Anthony Davies, Dermot Kelleher, Yuri Volkov, Jacinta Kelly and Mohamed Abuzakouk. The team examined duodenal biopsies from 14 untreated and 10 treated celiac patients and from 20 non-celiac control subjects. They also investigated tissue sections from six study group subjects before and after the development of gluten-sensitive enteropathy. The research team used an anti-Î±-tubulin antibody to conduct immunohistochemical studies on paraffin-embedded tissue sections. They found important differences in enterocyte morphology and intracellular cytoskeletal structures in the patients with proven celiac disease and those in the study group. Moreover, the team observed that these changes existed in the study group prior to any indication of enteropathy, as determined by standard microscopy. This is the first time researchers have used high content analysis to show specific details of enterocyte morphology. Such an approach permits doctors to quantitatively analyze enterocyte intracellular structure from standard biopsy samples and allows for detection of minute changes that develop before the classic histological lesion. This process could become important for improving the diagnosis of celiac disease. If doctors can spot celiac-related intestinal lesions before they develop, they can begin to prevent celiac disease before it develops and thereby save lives. Central European Journal of Biology Volume 3, Number 3 / September, 2008
Jefferson Adams posted an article in Celiac Disease & Gluten Intolerance ResearchCeliac.com 04/13/2009 - A team of Spanish researchers recently set out to determine rates and clinical status of gluten sensitive enteropathy (GSE) detected by mass blood screens. The researchers also sought to determine sensitivity of anti-transglutaminase (tTGA) and anti-endomysium antibodies (EmA) in diagnosis, and compliance with a gluten-free diet (GFD) and follow-up. The research team was made up of doctors Meritxell Mariné, Fernando Fernández-Bañares, Montserrat Alsina, Carme Farré, Montserrat Cortijo, Rebeca Santaolalla, Antonio Salas, Margarita Tomàs, Elias Abugattas, Carme Loras, Ingrid Ordás, Josep M Viver, and Maria Esteve. Researchers recruited one thousand, eight hundred and sixty eight subjects, who were the screened for tTGA and EmA. Positive screens were referred for duodenal biopsy, DQ2/DQ8 genotyping, clinical feature charting, blood tests, and densitometry. More than 98% of subjects showed tTGA levels below 2 U/mL, so researchers designated this as the baseline level for normality, and deemed results positive at or above this level if confirmed twice in a single sample. Researchers also charted adherence to a GFD and follow-up results. A total of 26 subjects (1.39%) showed positive tTGA and/or EmA results, Of those, 21 underwent biopsy, with results showing six Marsh â…¢ (one â…¢a, four â…¢b, one â…¢c), nine Marsh â… and six Marsh 0, with a GSE rate of 1:125. EmA sensitivity for GSE was 46.6% (11.1% for Marsh â… , 100% for Marsh â…¢), while tTGA, sensitivity was 93.3% (88.8% for Marsh â… , 100% for Marsh â…¢). All 15 patients with abnormal blood tests showed clinical manifestations related to GSE. Marsh â… and â…¢ subjects showed more abdominal pain than Marsh 0 (P = 0.029), and also showed more distention and diarrhea. The team saw no differences in the rates of osteopenia between Marsh â… and â…¢ (P = 0.608). They found that 66.7% of the 15 GSE patients complied with a gluten-free diet, and that 80% responded positively to the diet. 69.2% participated in follow-up study. This study showed positive blood screens in nearly 1.4% of those tested. The study showed frequent and clinically relevant rates of GSE among the general population. This confirms that celiac disease and related conditions are at least as common as the 1% figure commonly quoted, and indicate that when criteria are expanded to include less severe cases, they may be even higher. The study confirmed tTGA as the marker of choice, and showed that mass screening programs such as this one are helpful in spotting celiac disease early, and in referring people for treatment and follow-up before the disease develops into more costly and debilitating conditions often associated with untreated celiac disease. World J Gastroenterol. 2009 March 21; 15(11): 1331–1338.